IBDEI0Z3 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15840,1,3,0)
 ;;=3^Progressive Systemic Sclerosis
 ;;^UTILITY(U,$J,358.3,15840,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,15840,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,15841,0)
 ;;=M34.1^^61^765^92
 ;;^UTILITY(U,$J,358.3,15841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15841,1,3,0)
 ;;=3^CR(E)ST Syndrome
 ;;^UTILITY(U,$J,358.3,15841,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,15841,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,15842,0)
 ;;=M34.2^^61^765^313
 ;;^UTILITY(U,$J,358.3,15842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15842,1,3,0)
 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
 ;;^UTILITY(U,$J,358.3,15842,1,4,0)
 ;;=4^M34.2
 ;;^UTILITY(U,$J,358.3,15842,2)
 ;;=^5011780
 ;;^UTILITY(U,$J,358.3,15843,0)
 ;;=M34.81^^61^765^315
 ;;^UTILITY(U,$J,358.3,15843,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15843,1,3,0)
 ;;=3^Systemic Sclerosis w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,15843,1,4,0)
 ;;=4^M34.81
 ;;^UTILITY(U,$J,358.3,15843,2)
 ;;=^5011781
 ;;^UTILITY(U,$J,358.3,15844,0)
 ;;=M34.82^^61^765^316
 ;;^UTILITY(U,$J,358.3,15844,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15844,1,3,0)
 ;;=3^Systemic Sclerosis w/ Myopathy
 ;;^UTILITY(U,$J,358.3,15844,1,4,0)
 ;;=4^M34.82
 ;;^UTILITY(U,$J,358.3,15844,2)
 ;;=^5011782
 ;;^UTILITY(U,$J,358.3,15845,0)
 ;;=M34.83^^61^765^317
 ;;^UTILITY(U,$J,358.3,15845,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15845,1,3,0)
 ;;=3^Systemic Sclerosis w/ Polyneuropathy
 ;;^UTILITY(U,$J,358.3,15845,1,4,0)
 ;;=4^M34.83
 ;;^UTILITY(U,$J,358.3,15845,2)
 ;;=^5011783
 ;;^UTILITY(U,$J,358.3,15846,0)
 ;;=M34.89^^61^765^314
 ;;^UTILITY(U,$J,358.3,15846,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15846,1,3,0)
 ;;=3^Systemic Sclerosis NEC
 ;;^UTILITY(U,$J,358.3,15846,1,4,0)
 ;;=4^M34.89
 ;;^UTILITY(U,$J,358.3,15846,2)
 ;;=^5011784
 ;;^UTILITY(U,$J,358.3,15847,0)
 ;;=M34.9^^61^765^318
 ;;^UTILITY(U,$J,358.3,15847,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15847,1,3,0)
 ;;=3^Systemic Sclerosis,Unspec
 ;;^UTILITY(U,$J,358.3,15847,1,4,0)
 ;;=4^M34.9
 ;;^UTILITY(U,$J,358.3,15847,2)
 ;;=^5011785
 ;;^UTILITY(U,$J,358.3,15848,0)
 ;;=R21.^^61^765^297
 ;;^UTILITY(U,$J,358.3,15848,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15848,1,3,0)
 ;;=3^Rash/Nonspecific Skin Eruption
 ;;^UTILITY(U,$J,358.3,15848,1,4,0)
 ;;=4^R21.
 ;;^UTILITY(U,$J,358.3,15848,2)
 ;;=^5019283
 ;;^UTILITY(U,$J,358.3,15849,0)
 ;;=R23.3^^61^765^309
 ;;^UTILITY(U,$J,358.3,15849,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15849,1,3,0)
 ;;=3^Spontaneous Ecchymoses
 ;;^UTILITY(U,$J,358.3,15849,1,4,0)
 ;;=4^R23.3
 ;;^UTILITY(U,$J,358.3,15849,2)
 ;;=^5019295
 ;;^UTILITY(U,$J,358.3,15850,0)
 ;;=L03.113^^61^765^114
 ;;^UTILITY(U,$J,358.3,15850,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15850,1,3,0)
 ;;=3^Cellulitis of Right Upper Limb
 ;;^UTILITY(U,$J,358.3,15850,1,4,0)
 ;;=4^L03.113
 ;;^UTILITY(U,$J,358.3,15850,2)
 ;;=^5009033
 ;;^UTILITY(U,$J,358.3,15851,0)
 ;;=L03.114^^61^765^107
 ;;^UTILITY(U,$J,358.3,15851,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15851,1,3,0)
 ;;=3^Cellulitis of Left Upper Limb
 ;;^UTILITY(U,$J,358.3,15851,1,4,0)
 ;;=4^L03.114
 ;;^UTILITY(U,$J,358.3,15851,2)
 ;;=^5009034
 ;;^UTILITY(U,$J,358.3,15852,0)
 ;;=L03.115^^61^765^111
 ;;^UTILITY(U,$J,358.3,15852,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15852,1,3,0)
 ;;=3^Cellulitis of Right Lower Limb
 ;;^UTILITY(U,$J,358.3,15852,1,4,0)
 ;;=4^L03.115
